Hosted on MSN21h
Talazoparib-Enzalutamide Improves Survival in Metastatic CRPC
Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...
Pharmabiz11h
Pfizer’s Talzenna in combi with Xtandi improves survival outcomes in metastatic castration resistant prostate cancer
Pfizer’s Talzenna in combi with Xtandi improves survival outcomes in metastatic castration resistant prostate cancer: New York Saturday, February 15, 2025, 11:00 Hrs [IST] Pfize ...
GlobalData on MSN23h
Pfizer’s Talzenna gains 14-months OS lead over mCRPC SoC
Results from the company’s Talapro-2 trial saw a 38% reduction in the risk of death among HRR-mutated patients.
Hosted on MSN17h
Adding Radioligand to Enzalutamide Boosts OS in Metastatic CRPC
She noted the survival benefit with the combination was achieved even though 38% of patients in the enzalutamide-alone arm ...